Key Points
- AutoZone shares fell 1.75% to $2,805.17 on September 21, reaching a new 52-week low ahead of the company’s fiscal fourth-quarter earnings report.
- Oppenheimer lowered its price target from $4,300 to $3,500 while maintaining an outperform rating, adding to investor focus ahead of the results.
- Analysts expect $54.30 in quarterly earnings per share and $6.71 billion in revenue, with comparable-store sales, commercial growth, margins and fiscal 2027 guidance likely to be closely watched.
AutoZone shares are heading into the company’s fiscal fourth-quarter results under pressure after the stock reached a new 52-week low during Monday’s session. The shares closed at $2,805.17 on the New York Stock Exchange, down 1.75% from the previous close of $2,855.31.
The stock traded as low as $2,796.85 during the session, establishing another low for the year. Approximately 599,464 shares changed hands, highlighting a cautious market backdrop ahead of the company’s earnings announcement.
Analyst Target Cut Adds to Investor Focus
The decline came after Oppenheimer reduced its price target for AutoZone from $4,300 to $3,500 while maintaining an outperform rating. The adjustment adds another layer of uncertainty for investors already watching the stock’s weaker performance.
AutoZone was down approximately 14% year to date before the earnings report, according to the figures provided. The combination of a new 52-week low and a reduced price target means the upcoming results could provide an important test of expectations surrounding the company’s operating performance.
Fourth-Quarter Results Due Before the Open
AutoZone is scheduled to release its fiscal fourth-quarter results before the market opens on September 22. Analysts are expecting earnings of $54.30 per share and revenue of approximately $6.71 billion.
However, the headline revenue and earnings figures will not be the only factors investors are likely to consider. Comparable-store sales, commercial business growth and margins will provide additional insight into the strength of AutoZone’s underlying operations.
Fiscal 2027 Guidance Could Drive the Reaction
Forward guidance may be particularly important because the market is already pricing in a period of weaker share performance. Investors will be looking for management’s outlook for fiscal 2027 and whether expected sales, margins and operating conditions support a recovery in the company’s financial trajectory.
A strong quarterly result could therefore be assessed alongside the company’s forward expectations rather than in isolation. Conversely, weaker guidance could reinforce concerns reflected in the stock’s recent decline.
The Margin and Sales Picture Matters
AutoZone’s comparable-store performance will offer an indication of how customer demand is developing, while commercial growth can provide insight into another important part of the business. Margins will also remain a key area of attention as investors assess whether profitability is holding up alongside revenue growth.
These metrics could help determine whether the recent weakness in the share price reflects temporary market pressure or broader concerns about the company’s operating outlook.
What Investors May Watch Next
The immediate focus is now on AutoZone’s fiscal fourth-quarter results and management’s fiscal 2027 outlook. Investors may pay particular attention to whether earnings and revenue meet expectations, how comparable-store sales and commercial activity perform, and whether margins provide evidence of improving or deteriorating profitability. With the stock at a new 52-week low, the market’s response could depend as much on forward guidance as on the quarterly numbers themselves.
Comparison, examination, and analysis between investment houses
Leave your details, and an expert from our team will get back to you as soon as possible
* This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.
To read more about the full disclaimer, click here- sagi habasov
- •
- 5 Min Read
- •
- ago 5 hours
SKN | Can Aytu BioPharma’s Q4 Results Clarify Its Path Beyond Continued Losses?
Aytu BioPharma is set to release its fiscal fourth-quarter 2026 results after the U.S. market closes on September 22. The
- ago 5 hours
- •
- 5 Min Read
Aytu BioPharma is set to release its fiscal fourth-quarter 2026 results after the U.S. market closes on September 22. The
- Ronny Mor
- •
- 7 Min Read
- •
- ago 6 hours
SKN | Could MillerKnoll’s Q1 Earnings Reveal Whether Margin Pressure Is Temporary?
MillerKnoll is heading into its fiscal first-quarter 2027 earnings release with investors closely watching whether demand and profitability can withstand
- ago 6 hours
- •
- 7 Min Read
MillerKnoll is heading into its fiscal first-quarter 2027 earnings release with investors closely watching whether demand and profitability can withstand
- sagi habasov
- •
- 7 Min Read
- •
- ago 16 hours
SKN | Could Medicare GLP-1 Coverage Accelerate Eli Lilly’s Obesity Drug Growth?
Medicare Coverage Expands the GLP-1 Market Eli Lilly is seeing significant early demand from Medicare beneficiaries following the launch of
- ago 16 hours
- •
- 7 Min Read
Medicare Coverage Expands the GLP-1 Market Eli Lilly is seeing significant early demand from Medicare beneficiaries following the launch of
- omer bar
- •
- 6 Min Read
- •
- ago 22 hours
SKN | Can Novo Nordisk’s Post-Wegovy Strategy Restore Investor Confidence?
Novo’s Long-Term Strategy Fails to Calm Investors Novo Nordisk shares came under heavy pressure Monday after the Danish drugmaker unveiled
- ago 22 hours
- •
- 6 Min Read
Novo’s Long-Term Strategy Fails to Calm Investors Novo Nordisk shares came under heavy pressure Monday after the Danish drugmaker unveiled